Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED +1.63%72 EV-to-EBIT is 40.37 as of Aug. 20, 2026, which is 34% above its 10-year median of 30.22. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 72/100 and a GF Value™ of ₹452.70 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 687 Drug Manufacturers companies, Shilpa Medicare ranks worse than 79.91% on this metric.
The historical rank and industry rank for Shilpa Medicare's EV-to-EBIT or its related term are showing as below:
NSE:SHILPAMED'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11.12 Med: 30.22 Max: 168.24
Current: 40.37
During the past 13 years, the highest EV-to-EBIT of Shilpa Medicare was 168.24. The lowest was 11.12. And the median was 30.22.
NSE:SHILPAMED's EV-to-EBIT is ranked worse than 79.91% of 687
companies
in the Drug Manufacturers industry
Industry Median: 15.81
vs NSE:SHILPAMED: 40.37
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shilpa Medicare's Enterprise Value for the quarter that ended in Jun. 2026 was ₹117,036 Mil.
Shilpa Medicare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare EV-to-EBIT Related Terms
Shilpa Medicare EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's EV-to-EBIT falls into.
Shilpa Medicare's current Enterprise Value is ₹166,671 Mil.
Shilpa Medicare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (NSE:SHILPAMED) has a EV-to-EBIT of 40.37 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shilpa Medicare and its competitors. This is 34% above median its historical median of 30.22. Over the past decade, Shilpa Medicare's EV-to-EBIT has ranged from 11.12 to 168.24. According to the industry distribution chart, Shilpa Medicare ranks #549 out of 687 companies in the Drug Manufacturers industry, placing it in the top 79.9%.
Is Shilpa Medicare's EV-to-EBIT too high?
Shilpa Medicare's current EV-to-EBIT of 40.37 is 34% above median its 10-year median of 30.22. Over the past 10 years, this metric has ranged from a low of 11.12 to a high of 168.24. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Shilpa Medicare's value of 40.37 is 155.3% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #549 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shilpa Medicare has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #549 out of 687 companies for EV-to-EBIT. This places Shilpa Medicare in the lower half of its industry. The industry median EV-to-EBIT is 15.81. Shilpa Medicare's value of 40.37 is 155.3% above this benchmark. Historically, Shilpa Medicare's own EV-to-EBIT has ranged from 11.12 to 168.24 over the past decade. While the company's 10-year median is 30.22 vs. the industry median of 15.81, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current EV-to-EBIT of 40.37 is 155.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current EV-to-EBIT is 40.37, which is 34% above median its own 10-year median of 30.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹452.70, compared to a current price of ₹820.95 — trading 81.3% above its estimated fair value. The current EV-to-EBIT is 40.37, which is 34% above median its 10-year median of 30.22 and 155.3% above the Drug Manufacturers industry median of 15.81. Shilpa Medicare's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current EV-to-EBIT is 40.37 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹820.95 is trading 81.3% above its estimated GF Value™ of ₹452.70.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
EV-to-EBIT: 40.37 (34% above median its 10-year median of 30.22)
GF Value™: ₹452.70 vs. price of ₹820.95 (81.3% above fair value)
Industry Position: 155.3% above the Drug Manufacturers median (#549 of 687)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
72GF Score
Get the complete analysis for NSE:SHILPAMED
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
